Correlation Between VentureNet Capital and CytoMed Therapeutics

Can any of the company-specific risk be diversified away by investing in both VentureNet Capital and CytoMed Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining VentureNet Capital and CytoMed Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between VentureNet Capital Group and CytoMed Therapeutics Limited, you can compare the effects of market volatilities on VentureNet Capital and CytoMed Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in VentureNet Capital with a short position of CytoMed Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of VentureNet Capital and CytoMed Therapeutics.

Diversification Opportunities for VentureNet Capital and CytoMed Therapeutics

-0.11

Correlation Coefficient

VentureNet Capital  CytoMed Therapeutics

Good diversification

The 3 months correlation between VentureNet and CytoMed is -0.11. Overlapping area represents the amount of risk that can be diversified away by holding VentureNet Capital Group and CytoMed Therapeutics Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytoMed Therapeutics and VentureNet Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on VentureNet Capital Group are associated (or correlated) with CytoMed Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytoMed Therapeutics has no effect on the direction of VentureNet Capital i.e., VentureNet Capital and CytoMed Therapeutics go up and down completely randomly.

Pair Corralation between VentureNet Capital and CytoMed Therapeutics

Given the investment horizon of 90 days VentureNet Capital Group is expected to generate 20.39 times more return on investment than CytoMed Therapeutics. However, VentureNet Capital is 20.39 times more volatile than CytoMed Therapeutics Limited. It trades about 0.11 of its potential returns per unit of risk. CytoMed Therapeutics Limited is currently generating about 0.06 per unit of risk. If you would invest  0.01  in VentureNet Capital Group on December 21, 2024 and sell it today you would earn a total of  0.00  from holding VentureNet Capital Group or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	96.77%
Values	Daily Returns

VentureNet Capital Group  vs.  CytoMed Therapeutics Limited

VentureNet Capital

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in VentureNet Capital Group are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, VentureNet Capital displayed solid returns over the last few months and may actually be approaching a breakup point.

CytoMed Therapeutics

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in CytoMed Therapeutics Limited are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, CytoMed Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with VentureNet Capital and CytoMed Therapeutics

The main advantage of trading using opposite VentureNet Capital and CytoMed Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if VentureNet Capital position performs unexpectedly, CytoMed Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytoMed Therapeutics will offset losses from the drop in CytoMed Therapeutics' long position.

The idea behind VentureNet Capital Group and CytoMed Therapeutics Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.